Possible Heart Failure Exacerbation Associated with Rosiglitazone: Case Report and Literature Review

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Pharmacotherapy

• Publication date

  2003-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1592/phco.23.7.945.32721PMID 12885108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Guidelines for the evaluation and management of chronic heart failure].

  2003cited by this paper
• Frequency of inappropriate metformin prescriptions.

  2002cited by this paper
• Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group V: Management of Cardiovascular-Renal Complications

  2002cited by this paper
• PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes: Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis

  2002cited by this paper
• When are medication side effects due to the nocebo phenomenon

  2002cited by this paper
• Adaptation and maladaptation of the heart in diabetes: Part I: general concepts.

  2002cited by this paper
• Thiazolidinedione‐Induced Edema

  2002cited by this paper
• Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro.

  2002cited by this paper
• PPARs, Insulin Resistance and Type 2 Diabetes

  2001cited by this paper
• Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with Type 2 diabetes mellitus.

  2001cited by this paper
• Contraindications to metformin therapy in patients with Type 2 diabetes—a population‐based study of adherence to prescribing guidelines

  2001cited by this paper
• Pioglitazone Ameliorates Tumor Necrosis Factor-α–Induced Insulin Resistance by a Mechanism Independent of Adipogenic Activity of Peroxisome Proliferator–Activated Receptor-γ

  2001cited by this paper
• Relationship between serum tumor necrosis factor-α and insulin resistance in obese men with Type 2 diabetes mellitus

  2001cited by this paper
• Cardiomyopathy and heart failure in diabetes.

  2001cited by this paper
• Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction.

  2001cited by this paper
• The impact of heart failure on prognosis of diabetic and non‐diabetic patients with myocardial infarction: a 15‐year follow‐up study

  2001cited by this paper
• Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma.

  2001cited by this paper
• Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors.

  2001cited by this paper
• Pulmonary Edema Associated with Rosiglitazone and Troglitazone

  2001influential reference
• Potential Role of TNF-a in the Pathogenesis of Insulin Resistance and Type 2 Diabetes

  2000cited by this paper
• The role of tumor necrosis factor in the pathophysiology of heart failure.

  2000cited by this paper
• Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure.

  2000cited by this paper
• Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes.

  2000cited by this paper
• Epidemiology and clinical presentation of type 2 diabetes.

  2000cited by this paper
• Prevention of coronary heart disease in type 2 diabetes.

  2000cited by this paper
• Insulin resistance in chronic heart failure.

  2000cited by this paper
• Troglitazone-induced pulmonary edema.

  2000cited by this paper
• Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

  2000cited by this paper
• The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.

  1999cited by this paper
• TNF-alpha-induced migration of vascular smooth muscle cells is MAPK dependent.

  1999cited by this paper
• Pulmonary edema associated with troglitazone therapy.

  1999cited by this paper
• Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease.

  1999cited by this paper
• Diabetes mellitus and congestive heart failure. Further knowledge needed.

  1999cited by this paper
• Effect of troglitazone on body fat distribution in type 2 diabetic patients.

  1999cited by this paper
• Significant weight gain with rezulin therapy.

  1999cited by this paper
• TNF-α–Induced Migration of Vascular Smooth Muscle Cells Is MAPK Dependent

  1999cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Lactic acidosis in patients with diabetes treated with metformin.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro.

  1998cited by this paper
• Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group.

  1997cited by this paper
• The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010

  1997cited by this paper
• The effect of digoxin on mortality and morbidity in patients with heart failure.

  1997cited by this paper
• Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure.

  1997cited by this paper
• Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry.

  1996cited by this paper
• Pioglitazone attenuates diet-induced hypertension in rats.

  1995cited by this paper
• Diabetic Cardiomyopathy: A unique entity or a complication of coronary artery disease?

  1995cited by this paper
• Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.

  1995cited by this paper
• Insulin resistance in chronic heart failure.

  1994cited by this paper
• Antihypertensive effects of CS-045 treatment in obese Zucker rats.

  1993cited by this paper
• Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

  1992cited by this paper
• Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

  1992cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

  1991cited by this paper
• Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure.

  1991cited by this paper
• Hormonal effects of norepinephrine on acute glucose disposal in humans: a minimal model analysis.

  1988cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1988cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1987cited by this paper
• Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.

  1986cited by this paper
• Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure

  1986cited by this paper
• A method for estimating the probability of adverse drug reactions

  1981cited by this paper
• Diabetes and cardiovascular disease. The Framingham study.

  1979cited by this paper
• Role of diabetes in congestive heart failure: the Framingham study.

  1974cited by this paper
• Morbidity and Mortality in Diabetics In the Framingham Population: Sixteen Year Follow-up Study

  1974cited by this paper

• Effects of oral antidiabetic agents on the renin–angiotensin–aldosterone system

  2025cites this paper
• Research progress of PPARγ regulation of cholesterol and inflammation in Alzheimer's disease

  2023cites this paper
• Sheet 2 of 26 US 2010 / 0216883 A 1 Figure 2 PPAR

  2017cites this paper
• Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association.

  2016cites this paper
• Latest research and development trends in non-insulin anti-diabetics

  2013cites this paper
• The importance of synthetic drugs for type 2 diabetes drug discovery

  2013cites this paper
• Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation

  2013cites this paper
• Genetic Modification of MSCs for Pharmacological Screening

  2013cites this paper
• The Comorbidity Conundrum: A Focus on the Role of Noncardiovascular Chronic Conditions in the Heart Failure Patient

  2012cites this paper
• Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents

  2010cites this paper
• The effect of substituted thiophene and benzothiophene derivates on PPARγ expression and glucose metabolism

  2009cites this paper
• Peroxisome Proliferator‐Activated Receptor γ Modulation for the Treatment of Type 2 Diabetes

  2008cites this paper
• Cardiovascular risk of rosiglitazone: another perspective

  2008cites this paper
• Dietary Modulators of Peroxisome Proliferator-Activated Receptors: Implications for the Prevention and Treatment of Metabolic Syndrome

  2008cites this paper
• Drug Class Review: Thiazolidinediones: Final Report Update 1

  2008cites this paper
• HEART FAILURE DUE TO ROSIGLITAZONE AT OLDER PATIENT

  2008cites this paper
• Pioglitazone and Nonalcoholic Steatohepatitis

  2007cites this paper
• Safety issues and prospects for future generations of PPAR modulators.

  2007cites this paper
• Thiazolidinediones and Heart Failure

  2007cites this paper
• Dietary abscisic acid ameliorates glucose tolerance and obesity-related inflammation in db/db mice fed high-fat diets.

  2007cites this paper
• Abscisic acid ameliorates glucose tolerance and obesity-induced inflammation

  2007cites this paper
• Elevated Creatine Kinase and Myalgia in a Patient Taking Rosiglitazone

  2007cites this paper
• PPARγ agonists: safety issues in heart failure

  2007cites this paper
• Investigational PPAR-γ agonists for the treatment of Type 2 diabetes

  2006cites this paper
• Today's challenges and tomorrow's opportunities: ligands to peroxisome proliferator‐activated receptors as therapies for type 2 diabetes and the metabolic syndrome

  2006cites this paper
• Do thiazolidinediones cause heart failure? A critical review.

  2006cites this paper
• Recent findings concerning thiazolidinediones in the treatment of diabetes

  2006cites this paper
• Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes.

  2006cites this paper
• Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption

  2005cites this paper
• Diabetes mellitus and its treatment

  2005cites this paper
• Thiazolidinediones and Insulin

  2005cites this paper
• Risk of Heart Failure with the Use of Thiazolidinediones within a Medicaid Population

  2005cites this paper
• 42 - Insulin, glucagon, and oral hypoglycemic drugs

  2005cites this paper
• Clinical and Economic Evaluation of Two Thiazolidinediones in the Management of Diabetes

  2005cites this paper
• Thiazolidinediones and congestive heart failure—exacerbation or new onset of left ventricular dysfunction?

  2004cites this paper
• The edematogenic properties of insulin.

  2004cites this paper
• Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms.

  2004cites this paper